{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:16:24Z","timestamp":1786115784976,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Washington University, Institute for Public Health, Center for Dissemination and Implementation"},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013395","name":"Taylor Family Institute for Innovative Psychiatric Research, School of Medicine, Washington University in St. Louis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013395","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Implement Sci Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pediatric-onset multiple sclerosis (POMS) is a chronic autoimmune disease of the central nervous system that requires lifelong care. Long-term outcomes in POMS depend on both early therapeutic intervention and sustained continuity of specialty care into adulthood. However, there is a discrepancy between the speed and consistency at which pharmaceutical disease-modifying therapies and best practices for transition-to-adult care are incorporated into clinical practice. While pharmaceutical disease-modifying therapies have been rapidly incorporated into routine practice, uptake of best practices for transition-to-adult care has been inconsistent and slow, despite evidence-based guidelines and models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>There is an urgent need for the implementation of transition-to-adult care interventions to \u201ccatch up\u201d to that of disease-modifying therapies for POMS. Closing this gap is important because without a system of continuous care, patients lose access to disease-modifying therapies, negating the benefits of early and rapid uptake and jeopardizing long-term neurologic stability and outcomes as youth with multiple sclerosis (MS) grow into adulthood. This paper applies the Framework to Assess Speed of Translation (FAST) to examine this contrast in implementation pace and understand why pharmaceutical disease-modifying therapies have diffused rapidly, whereas innovations to support transitioning to adult care have not. We examine how innovation, adopter and contextual factors affect the diffusion and uptake of innovations in POMS, illustrating how interventions with observable relative advantage, strong champions, and compatibility with existing medical paradigms are propelled through the system, whereas interventions that are perceived as more complex, diffuse in ownership, and less visibly linked to outcomes are hindered. We argue that future efforts to improve transition-to-adult care in POMS must systematically identify and address determinants of pace that have slowed progress to date. Guided by the Designing for Accelerated Translation (DART) framework, we propose strategies for developing and mapping transition-to-adult care interventions that emphasize rapid translation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our objective is to facilitate the acceleration of translation of evidence-based transition-to-adult care practices in POMS so that continuity of care keeps pace with therapeutic innovation, maximizing long-term outcomes for this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s43058-026-01069-9","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T04:52:03Z","timestamp":1785991923000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disproportionate pace of evidence-based care implementation in pediatric-onset multiple sclerosis: consequences and opportunities"],"prefix":"10.1186","volume":"7","author":[{"given":"Claudia","family":"Gambrah-Lyles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex T.","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"1069_CR1","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26:1816\u201321.","journal-title":"Mult Scler"},{"key":"1069_CR2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/0883073819845827","volume":"34","author":"A Jeong","year":"2019","unstructured":"Jeong A, Oleske DM, Holman J. Epidemiology of pediatric-onset multiple sclerosis: A systematic review of the literature. J Child Neurol. 2019;34:705\u201312.","journal-title":"J Child Neurol"},{"key":"1069_CR3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.msard.2013.06.004","volume":"3","author":"LA Benson","year":"2014","unstructured":"Benson LA, et al. Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years. Mult Scler Relat Disord. 2014;3:186\u201393.","journal-title":"Mult Scler Relat Disord"},{"key":"1069_CR4","doi-asserted-by":"publisher","first-page":"e2764","DOI":"10.1212\/WNL.0000000000007647","volume":"92","author":"KA McKay","year":"2019","unstructured":"McKay KA, Hillert J, Manouchehrinia A. Long-term disability progression of pediatric-onset multiple sclerosis. Neurology. 2019;92:e2764\u201373.","journal-title":"Neurology"},{"key":"1069_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13561-024-00478-7","volume":"14","author":"NA Gallehzan","year":"2024","unstructured":"Gallehzan NA, et al. Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing-remitting multiple sclerosis: a systematic review. Health Econ Rev. 2024;14:12.","journal-title":"Health Econ Rev"},{"key":"1069_CR6","doi-asserted-by":"crossref","unstructured":"Balas EA, Boren SA. Managing clinical knowledge for health care improvement. Yearb Med Inf. 2000;65\u201370.","DOI":"10.1055\/s-0038-1637943"},{"key":"1069_CR7","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1001\/jamaneurol.2023.2125","volume":"80","author":"M Henderson","year":"2023","unstructured":"Henderson M, et al. Initiation patterns of disease-modifying therapies for multiple sclerosis among US adults and children, 2001 through 2020. JAMA Neurol. 2023;80:860\u20137.","journal-title":"JAMA Neurol"},{"key":"1069_CR8","doi-asserted-by":"crossref","unstructured":"Fisher KS, Cuascut FX, Rivera VM, Hutton GJ. Current advances in pediatric onset multiple sclerosis. Biomedicines 2020;8.","DOI":"10.3390\/biomedicines8040071"},{"key":"1069_CR9","doi-asserted-by":"publisher","first-page":"e20182587","DOI":"10.1542\/peds.2018-2587","volume":"142","author":"PH White","year":"2018","unstructured":"White PH, et al. Supporting the Health Care Transition from adolescence to adulthood in the Medical Home. Pediatrics. 2018;142:e20182587.","journal-title":"Pediatrics"},{"key":"1069_CR10","doi-asserted-by":"crossref","unstructured":"ECTRIMS. 2024 \u2013 poster Mult Scler. 2024;30:125\u2013680.","DOI":"10.1177\/13524585241269219"},{"key":"1069_CR11","doi-asserted-by":"publisher","first-page":"e13304","DOI":"10.1111\/cch.13304","volume":"50","author":"E Thoby","year":"2024","unstructured":"Thoby E, Veras J, Nallapati S, Jimenez ME, Bhise V. No one really plans to have multiple sclerosis: Transition readiness and quality of life in paediatric multiple sclerosis. Child Care Health Dev. 2024;50:e13304.","journal-title":"Child Care Health Dev"},{"key":"1069_CR12","doi-asserted-by":"crossref","unstructured":"Sawicka K, Jones A, Overholt SACTRIMS. Forum 2020 - Poster session 1. Mult Scler J 2020:538;16\u201389.","DOI":"10.1177\/1352458520917096"},{"key":"1069_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s43477-022-00045-4","volume":"2","author":"E Proctor","year":"2022","unstructured":"Proctor E, et al. FAST: A framework to assess speed of translation of health innovations to practice and policy. Glob Implement Res Appl. 2022;2:107\u201319.","journal-title":"Glob Implement Res Appl"},{"key":"1069_CR14","first-page":"109","volume":"26","author":"P Mack","year":"1985","unstructured":"Mack P, Rogers EM. Diffus Innovations Technol Cult. 1985;26:109.","journal-title":"Diffus Innovations Technol Cult"},{"key":"1069_CR15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:777\u201388.","journal-title":"Neurology"},{"key":"1069_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/DBP.0000000000001024","volume":"43","author":"VWL Tsang","year":"2022","unstructured":"Tsang VWL, Fletcher S, Jassemi S, Smith S. Youth, caregiver, and provider perception of the transition from pediatric to adult care for youth with chronic diseases. J Dev Behav Pediatr. 2022;43:197\u2013205.","journal-title":"J Dev Behav Pediatr"},{"key":"1069_CR17","first-page":"CD009794","volume":"4","author":"F Campbell","year":"2016","unstructured":"Campbell F, et al. Transition of care for adolescents from paediatric services to adult health services. Cochrane Database Syst Rev. 2016;4:CD009794.","journal-title":"Cochrane Database Syst Rev"},{"key":"1069_CR18","doi-asserted-by":"crossref","unstructured":"Krupp L et al. Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIGMS Study. BMJ Neurol Open 2022;4:e000215.","DOI":"10.1136\/bmjno-2021-000215"},{"key":"1069_CR19","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.0887-378X.2004.00325.x","volume":"82","author":"T Greenhalgh","year":"2004","unstructured":"Greenhalgh T, Robert G, Macfarlane F, Bate P, Kyriakidou O. Diffusion of innovations in service organizations: systematic review and recommendations. Milbank Q. 2004;82:581\u2013629.","journal-title":"Milbank Q"},{"key":"1069_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1017\/cts.2019.386","volume":"3","author":"AT Ramsey","year":"2019","unstructured":"Ramsey AT, et al. Designing for Accelerated Translation (DART) of emerging innovations in health. J Clin Transl Sci. 2019;3:53\u20138.","journal-title":"J Clin Transl Sci"}],"container-title":["Implementation Science Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43058-026-01069-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43058-026-01069-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43058-026-01069-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T04:52:15Z","timestamp":1785991935000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43058-026-01069-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1069"],"URL":"https:\/\/doi.org\/10.1186\/s43058-026-01069-9","relation":{},"ISSN":["2662-2211"],"issn-type":[{"value":"2662-2211","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study did not involve human participants, human data, or human biological materials. Therefore, ethics committee or Institutional Review Board (IRB) approval was not required. As no human participants were involved, informed consent to participate was not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"143"}}